SCHEMBL6433655

SCHEMBL6433655

CC(C)(C)OC(=O)CN(C(=O)c1ccc2c(Cl)cnc(Cl)c2c1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
KMT2A Q03164 2/20 0.36
BACE1 P56817 1/20 0.35
PLAU P00749 1/20 0.35
MEN1 O00255 1/20 0.35
GSTO1 P78417 1/20 0.35
PRSS12 P56730 1/20 0.34
HTT P42858 1/20 0.34
F2 P00734 2/20 0.34
TP53 P04637 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
ADORA2A P29274 1/20 0.32
MAPT P10636 1/20 0.32
NR1H4 Q96RI1 1/20 0.32
ACHE P22303 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433874 0.85 F2 (0.37) ALDH1A1SMN1; SMN2KMT2ABACE1PLAU
SCHEMBL7403972 0.85 PLAU (0.44) ALDH1A1SMN1; SMN2KMT2ABACE1PLAU
SCHEMBL6433018 0.84 CFTR (0.38) ALDH1A1KMT2APLAUMEN1HTT
SCHEMBL7368849 0.83 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2KMT2AMEN1PRSS12
SCHEMBL6433083 0.78 PLAU (0.57) ALDH1A1SMN1; SMN2KMT2APLAUMEN1
SCHEMBL6434696 0.77 NR1D1 (0.43) KMT2APLAUMEN1
SCHEMBL6434389 0.76 PTPRC (0.49) ALDH1A1KMT2AMEN1MAPT
SCHEMBL6433264 0.74 ROCK2 (0.44)
SCHEMBL6433131 0.73 PLAU (0.58) ALDH1A1SMN1; SMN2PLAUMAPT
SCHEMBL6436909 0.73 DGAT2 (0.50) ALDH1A1SMN1; SMN2KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002000651-A2 FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-01-03 WO claimed
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 ALDH1A1 2641/4885SMN1; SMN2 2612/4885KMT2A 4810/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 ALDH1A1 2641/4885SMN1; SMN2 2612/4885KMT2A 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.